Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases

Authors
Citation
M. Aviram, Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases, FREE RAD RE, 33, 2000, pp. S85-S97
Citations number
88
Categorie Soggetti
Biochemistry & Biophysics
Journal title
FREE RADICAL RESEARCH
ISSN journal
10715762 → ACNP
Volume
33
Year of publication
2000
Supplement
S
Pages
S85 - S97
Database
ISI
SICI code
1071-5762(2000)33:<S85:ROHSOO>2.0.ZU;2-1
Abstract
Under oxidative stress, which is associated with atherosclerosis, oxidative modifications of LDL take place. A major effect of antioxidants in the LDL environment is to prevent the formation of oxidized LDL during atherogenes is. The question that arises is what are the body's capabilities to inhibit LDL oxidation and to remove and/or to neutralize atherogenic Ox-LDL when f ormed. Strategies to reduce LDL oxidation and atherogenesis can involve the enrichment of the LDL and arterial cells with potent antioxidants that can prevent oxidative damage to the arterial wall. There seems to be a clear cause and effect relationship between LDL oxidati on and atherosclerosis. Atherosclerosis is a multifactorial disease and LDL is oxidized by all major cells of the arterial wall during the development of atherosclerosis via more than one mechanism. The various LDL oxidation pathways produce several lipid peroxidation products such as isoprostanes f rom arachidonic, eicosapentaenoic and docosahexaenoic acids, oxysterols fro m unesterified and esterified cholesterol, hydroxy fatty acids, lipid perox ides and aldehydes. Thus, one single assay of lipid peroxidation is probabl y not sufficient to serve as a marker for cardiovascular risk and there is a need for measurements of several markers. The use of biomarkers provides a logical scientific basis for major intervention trials of antioxidants; s uch trials will, in turn, eventually validate or disprove the biomarker con cept. Any intervention trial that does take place should be accompanied by measurements of one or more relevant biomarkers at intervals during the stu dy. If the endpoint of the trial is disease incidence or mortality, such st udies will help to validate or disprove the biomarker concept. They might a lso help to explore the possibility that in vivo levels of oxidative lipid damage are early predictors of subsequent development of cardiovascular dis ease. In addition, specific antioxidants in serum, as well as serum paraoxonase a ctivity can provide very useful information on the risk for cardiovascular diseases. For vascular disease risk, in addition to the markers in use for lipid pero xidation, there is a need to include also markers for endothelial dysfuncti on, monocyte adhesion, macrophage uptake of lipoproteins, thrombotic, and i nflammatory processes.